GOV.UK gov.uk 2026-07-01 13:35

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer

As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close review.  

Read full article at GOV.UK ↗

This summary is provided by Daily Junction. The original article is published by GOV.UK and all rights remain with the original publisher.

Related coverage on Daily Junction

Daily Briefing

The day's biggest stories in one free email. Join 12,648 readers.